Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression | Zendy

Martina Sanlorenzo | Zendy; Igor Vujic | Zendy; Adil Daud | Zendy; Alain P. Algazi | Zendy; Matthew A. Gubens | Zendy; Sara Alcántara Luna | Zendy; Kevin Lin | Zendy; Pietro Quaglino | Zendy; Klemens Rappersberger | Zendy; Susana OrtizUrda | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

Author(s) -

Martina Sanlorenzo,

Igor Vujic,

Adil Daud,

Alain P. Algazi,

Matthew A. Gubens,

Sara Alcántara Luna,

Kevin Lin,

Pietro Quaglino,

Klemens Rappersberger,

Susana OrtizUrda

Publication year - 2015

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2015.1916

Subject(s) - pembrolizumab , medicine , adverse effect , hypopigmentation , skin cancer , dermatology , clinical trial , lung cancer , regimen , melanoma , cancer , surgery , immunotherapy , cancer research

Immunomodulatory anticancer drugs, such as the anti-programmed death-1 drug pembrolizumab, have shown promising results in trials, and more patients will receive such treatments. Little is known about cutaneous adverse events (AEs) caused by these drugs and their possible correlation with treatment response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research